Food and Drug Administration

Oncologic Drugs Advisory Committee

September 24, 2002

Slides

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

IRESSA (ZD1839) Monotherapy for Non-Small Cell Lung Cancer (NSCLC), Introduction, Dr. George Blackledge, MD, AstraZeneca Pharmaceuticals  htm   ppt

The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer, Dr. Frances Shepherd, MD, U. of Toronto   htm   ppt

IRESSA Clinical Efficacy, Dr. Ronadl Natale, MD, Cedar Sinai Comprehensive Cancer Ctr.   htm   ppt

IRESSA (ZD1839) Safety Profile, Dr. Alan Sandler, MD, Vanderbilt University   htm   ppt

IRESSA Summary, Dr. George Blackledge, MD, AstraZeneca Pharmaceuticals   htm   ppt

NDA 21-399 ZD1839 for Treatment of NSCLC, FDA Presentation   htm   ppt